Andrew Richardson - Parkinsons Disease Competition Entry
Visit link:
Andrew Richardson - Parkinsons Disease Competition Entry.mov - Video
Parkinson's Disease Symptoms: Tremor, Posture, Gait and Balance Improve with TMJ Treatment – Video
TMJ patient treated by Dr.
Read the rest here:
Parkinson's Disease Symptoms: Tremor, Posture, Gait and Balance Improve with TMJ Treatment - Video
Tai chi may help Parkinson's patients, study concludes
LOS ANGELES — A six-month program of tai chi exercises helped people with various stages of Parkinson's disease improve stability, their ability to walk and reduced the frequency of falls.
A study released this month in the New England Journal of Medicine compared a six-month tailored tai chi program to resistance training and stretching to see which was most effective at improving functional movement, walking and balance for Parkinson's patients.
Researchers randomly assigned 195 men and women ages 40 to 85 who were in stages one to four of Parkinson's disease (on a scale of one to five). Parkinson's is a neurological disorder caused by a loss of neurons that produce dopamine, a chemical involved with muscle function and movement coordination. It can result in tremors, stiffness, poor coordination and more difficulty doing daily activities. It also can lead to a higher risk of falls, which can cause serious injuries.
Tai chi, a discipline that incorporates slow, deliberate movements, plus breathing, has health benefits that include reducing stress and improving balance and posture.
The study participants were randomly assigned to hourlong, twice-weekly sessions of tai chi, resistance training or stretching, for six months. Researchers assessed their status at the beginning of the study, at three and six months, and three months after the study ended.
The tai chi participants did better than the stretching group on a few measures: leaning without losing balance, having better directional control of their body and walking skills. They outperformed the resistance-training group on balance and stride length. Those in the tai chi group also reduced their frequency of falls more than the stretching group, and they were on a par with the resistance group.
Three months after the study ended, those in the tai chi group were able to maintain the benefits they had gained.
"Since many training features in the program are functionally oriented," Oregon Research Institute scientist Fuzhong Li said, "the improvements in the balance and gait measures that we demonstrated highlight the potential of Tai Chi-based movements in rehabilitating patients with these types of problems and, consequently, easing cardinal symptoms of Parkinson's disease and improving mobility, flexibility, balance and range of motion." Li was the lead author of the study.
He added that tai chi has several advantages: "It is a low-cost activity that does not require equipment, it can be done anywhere, at any time, and the movements can be easily learned. It can also be incorporated into a rehabilitation setting as part of existing treatment. Similarly, because of its simplicity, certain aspects of this Tai Chi program can also be prescribed to patients as a self-care/home activity."
Read more here:
Tai chi may help Parkinson's patients, study concludes
Parkinson's diagnosis guide created for Canadian MDs
Patients with symptoms of Parkinson's disease have often been misdiagnosed and told they're merely feeling the physical affects of the aging process. A new guideline developed for Canadian doctors by Parkinson's specialists hopes to reduce the number of misdiagnoses. (iStock)
A specialist with the Ottawa Hospital has helped to develop the first ever national guidelines for diagnosing Parkinson's, an often-misdiagnosed disease with subtle symptoms.
Accurately diagnosing the degenerative disorder of the central nervous system is confusing for some physicians because many of the symptoms such as tremors or a general slowing down can be brushed off as gradual physical wear-and-tear from old age, said Dr. David Grimes, director of Ottawa Hospital's Parkinson's Disease and Movements Disorders Clinic.
"It's not like having a stroke, where something dramatic happens all of a sudden, and so it's one of those conditions where symptoms creep into the picture and go on for many months, or sometimes years," Grimes said. "They're seeing their family doctor, and they're saying their sore shoulder is from this, or the hand's not moving because they have just a little bit of Arthritis, and so it can take quite a while before they're able to come up with the right diagnosis."
In a bid to help patients get the timely treatment and therapies they need, Grimes worked with other specialists for five years to create a tool for doctors across Canada that would help them more accurately diagnose Parkinson's patients in the early stages, before the disease progresses.
Paul Wing and Nick Kaethler count themselves among those who feel they may have lost time as far as being able to manage the disease due to delayed diagnosis.
Wing, whose doctor told him he was likely suffering from anxiety, didn't find out he actually had Parkinson's for eight months.
"It's really disconcerting. You're thinking, do I have AHLS, do I have MS, am I depressed? Is it cancer? It could be anything," Wing said. "It's hard to fight the good fight. It's hard when you don't have an enemy to fight."
Kaethler said he was told by his doctor, "You're just getting old. Live with it."
It took Kaethler five years to discover his enemy was Parkinson's.
Continued here:
Parkinson's diagnosis guide created for Canadian MDs
Parkinson's Disease Treatment – Patient Testimony "Lad" – Video
Lad has been diagnosed with Parkinson's Disease and was brought to Florida Detox
Continue reading here:
Parkinson's Disease Treatment - Patient Testimony "Lad" - Video
Patient-Derived Stem Cells Could Improve Drug Research For Parkinson's
NIH-funded study shows cells from different patients have unique drug responses
Researchers have taken a step toward personalized medicine for Parkinson's disease, by investigating signs of the disease in patient-derived cells and testing how the cells respond to drug treatments. The study was funded by the National Institutes of Health.
The researchers collected skin cells from patients with genetically inherited forms of Parkinsons and reprogrammed those cells into neurons. They found that neurons derived from individuals with distinct types of Parkinson's showed common signs of distress and vulnerability in particular, abnormalities in the cellular energy factories known as mitochondria. At the same time, the cells' responses to different treatments depended on the type of Parkinson's each patient had.
The results were published in Science Translational Medicine.
"These findings suggest new opportunities for clinical trials of Parkinsons disease, in which cell reprogramming technology could be used to identify the patients most likely to respond to a particular intervention," said Margaret Sutherland, Ph.D., a program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS).
A consortium of researchers conducted the study with primary funding from NINDS. The consortium is led by Ole Isacson, M.D., Ph.D., a professor of neurology at McLean Hospital and Harvard Medical School in Boston.
The NINDS consortium's first goal was to transform the patients' skin cells into induced pluripotent stem (iPS) cells, which are adult cells that have been reprogrammed to behave like embryonic stem cells. The consortium researchers then used a combination of growth conditions and growth-stimulating molecules to coax these iPS cells into becoming neurons, including the type that die in Parkinson's disease.
Parkinson's disease affects a number of brain regions, including a motor control area of the brain called the substantia nigra. There, it destroys neurons that produce the chemical dopamine. Loss of these neurons leads to involuntary shaking, slowed movements, muscle stiffness and other symptoms. Medications can help manage the symptoms, but there is no treatment to slow or stop the disease.
Most cases of Parkinson's are sporadic, meaning that the cause is unknown. However, genetics plays a strong role. There are 17 regions of the genome with common variations that affect the risk of developing Parkinson's disease. Researchers have also identified nine genes that, when mutated, can cause the disease.
Dr. Isacson and his collaborators derived iPS cells from five people with genetic forms of Parkinson's disease. By focusing on genetic cases, rather than sporadic cases, they hoped they would have a better chance of seeing patterns in the disease process and in treatment responses. Three of the individuals had mutations in a gene called LRRK2, and two others were siblings who had mutations in the gene PINK1. The researchers also derived iPS cells from two of the siblings' family members who did not have Parkinson's or any known mutations linked to it.
View original post here:
Patient-Derived Stem Cells Could Improve Drug Research For Parkinson's
How Parkinson’s Disease starts and spreads
July 6, 2012 How Parkinsons Disease starts and spreads
Anonymous Science Daily The Daily Item Fri Jul 06, 2012, 02:00 PM EDT
PHILADELPHIA
Injection of a small amount of clumped protein triggers a cascade of events leading to a Parkinsons-like disease in mice, according to an article published in the Journal of Experimental Medicine and reported by Science Daily.
Progressive accumulation of clumps of the protein alpha-synuclein in the brains of patients with Parkinsons disease coincides with the onset of motor dysfunction. However, whether these clumps are sufficient to trigger neurodegeneration, and how these clumps spread throughout the brain, remained unclear.
To answer these questions, a team led by Virginia M.Y. Lee at the University of Pennsylvania School of Medicine studied mice expressing a mutated form of alpha-synuclein found in patients with Parkinsons disease. These mice show symptoms of disease around one year of age but not earlier.
Lee and colleagues found that injecting preformed clumps of human alpha-synuclein into the brains of young mice accelerated disease onset and severity. These clumps seemed to act as seeds that recruited even the mouse version of alpha-synuclein into new clumps, which then spread throughout the brain. The pattern of spreading from neuron to neuron suggests that the clumps may hijack the highway traveled by normal brain signals.
These findings suggest that Parkinsons disease, like other neurodegenerative diseases including Alzheimers, may start and progress due to abnormal aggregation and accumulation of proteins within the brain. What gets these clumps going in the first place remains unclear.
Continued here:
How Parkinson’s Disease starts and spreads
Painting in park raises Parkinson's awareness
IRVINE Dozens gathered at Mason Regional Park on Saturday to paint pieces of what will be an art installment to raise awareness for Parkinson's disease.
The second annual Unity Barbecue featured artist Jack Knight, who will take the pieces of tubing, tiles and canvas and create a piece to hang on the walls of Aliso Viejo-based Parkinson's in Balance.
Visitors are shown a tile to be painted at the 2nd Annual Painting for Parkinson's and Parkinson's Unity BBQ event held at Mason Regional Park in Irvine on Saturday.
STUART PALLEY, THE ORANGE COUNTY REGISTER
ADVERTISEMENT
The event drew those affected by the disease and offered an afternoon of escape.
"I try to pick something that is therapeutic," said Allison Conway, founder of Parkinson's in Balance. "I find it so calming to be able to sit here and create something."
Her painted tile read, "I make Parkinson's look good."
This is the second year Conway, 35, has held the Unity Barbecue in an effort to raise awareness for an illness she knows well.
Conway was diagnosed with an auto-immune disease at age 13, colon cancer at age 24 and young onset Parkinson's at age 32.
See the article here:
Painting in park raises Parkinson's awareness
Interest being gauged for Parkinson's support group in Steamboat
Dr. Ralph Dittman
Steamboat Springs A part-time Steamboat Springs resident who has lived with Parkinsons disease for 14 years is seeking people who would be interested in participating in a support group.
What were doing is taking a head count to see how many people are interested, Dr. Ralph Dittman said. If they are interested, they need to raise their hands now.
Dittman, who splits his time between Steamboat and Houston, was a surgeon before Parkinsons came into his life at age 51.
The disease causes certain cells in the brain to become inactive, causing loss of motor functions and some neurologic functions. Notable Parkinsons sufferers include Muhammad Ali and Michael J. Fox.
The disease did not allow Dittman to be a surgeon anymore, so for the past eight years, he has been working in the laboratory and has become a renowned stem cell researcher and has published several novels.
Dittman thinks there are people in the community who could benefit greatly from a Parkinsons support group, especially those who take care of people suffering from the disease.
Theyre the people that take the real brunt of this thing, Dittman said. Theyre the ones that really need the help.
He said that to form the group, he needs to find at least 20 people who want to participate.
View original post here:
Interest being gauged for Parkinson's support group in Steamboat
Ludzik won't be bullied by Parkinson's disease
Steve Ludzik woke up one day and realized he'd traveled this road before.
When I was in grade six, there was a kid who would wait for me after school and slap me around, Ludzik recalls. I was just a skinny, little kid, and one night I came home with a black eye after he beat me up.
In today's America, there are protocols for handling bullies. In 1960s Canada, there was only one way to solve the problem.
My mom was an angel, and when she found out what was going on, she got right on the phone and said she would straighten it out, Ludzik said. My dad said, 'Put that phone down!'
My dad told me that when I get out of school tomorrow, get the drop on this kid and hit him, and then keep hitting him.
Like all bullies, the guy was a coward. I grabbed him the next day and throttled him. I never had another problem, and that kid never bothered anyone after that.
That's how we were raised. Take care of it yourself and don't get pushed around.
The 51-year-old Ludzik had been thinking about that time in his life early this year. It was eating away at his conscience. He felt what he was doing was wrong.
I looked at my own kids and I knew what I had to do, Ludzik said by phone from Niagara Falls a couple of days ago. I said, 'I'm not going to get kicked around by Parkinson's disease.' Not anymore.
That's when Ludzik announced to the world that he was ill.
See the original post:
Ludzik won't be bullied by Parkinson's disease
Study supports urate protection against Parkinson's disease, hints at novel mechanism
Public release date: 23-May-2012 [ | E-mail | Share ]
Contact: Mike Morrison mdmorrison@partners.org 617-724-6425 Massachusetts General Hospital
Use of the antioxidant urate to protect against the neurodegeneration caused by Parkinson's disease appears to rely on more than urate's ability to protect against oxidative damage. In the May issue of the open-access journal PLoS One, researchers from the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND) describe experiments suggesting the involvement of a novel mechanism in urate's protection of cultured brain cells against Parkinson's-like damage.
"Our experiments showed, unexpectedly, that urate's ability to protect neurons requires the presence of neighboring cells called astrocytes," says Michael Schwarzschild, MD, PhD, of MGH-MIND, the study's senior author. "The results suggest there may be multiple ways that raising urate could help protect against neurodegeneration in diseases like Parkinson's and further support the development of treatments designed to elevate urate in the brain." Schwarzschild and colleagues in the Parkinson's Study Group currently are conducting a clinical trial investigating one approach to that strategy.
Characterized by tremors, rigidity, difficulty walking and other symptoms, Parkinson's disease is caused by destruction of brain cells that produce the neurotransmitter dopamine. Several epidemiological studies suggested that healthy people with elevated levels of urate, a normal component of the blood, may have a reduced risk of developing Parkinson's disease, and investigations by Schwarzschild's team found that Parkinson's patients with higher naturally occuring urate levels had slower progression of their symptoms.
The current study was designed to investigate whether both added urate and urate already present within the cells protect cultured dopamine-producing neurons against Parkinson-like degeneration. In addition, since previous studies suggested that urate's protective effects depended on the presence of astrocytes star-shaped cells of the central nervous system that provide both structural and metabolic support to neurons the MGH-MIND team explored how the presence of astrocytes affects the ability of urate to protect against damage induced by MPP+, a toxic molecule that produces the same kind of neurodegeneration seen in Parkinson's and is widely used in research studies.
The experiments showed that, while added urate reduced MPP+-induced cell death by about 50 percent in cultured dopamine-producing mouse neurons, urate treatment virtually eliminated neuronal death in cultures containing both neurons and astrocytes. They also showed that reducing intracellular urate levels by induced expression of the enzyme that breaks it down increased neuronal vulnerability to MPP+ toxicity significantly in cultures that included astrocytes but only slightly in neuron-rich cultures. The fact that the presence of astrocytes greatly increases the protection of both externally applied urate and urate produced within cells indicates that the effect depends on more than urate's ability to directly protect neurons against oxidative stress.
"A valuable next step will be determining whether endogenous urate is protective in live animal models of Parkinson's disease," says Schwarzschild. "It also will be important to determine whether we can selectively increase urate levels in brain cells by targeting urate transporter molecules. The approach now in early clinical trials examines whether treatment with the urate precursor inosine, which increases urate levels throughout the body, can slow the progression of the disease. If we could raise urate levels in brain cells without changing them in the rest of the body, we could avoid the risks of of excessive urate, which when accumulated in joints can cause gout."
###
Schwarzschild is an associate professor of Neurology at Harvard Medical School. Sara Cipriani, MD, of MGH-MIND is the lead and corresponding author of the PLoS One report. The study was supported by grants from the National Institutes of Health, the Department of Defense and the American Parkinson's Disease Association.
Read this article:
Study supports urate protection against Parkinson's disease, hints at novel mechanism
Parkinson's group to meet
MERIDIAN When the Meridian Parkinson's Disease Support Group first met a few months ago there were only four people in attendance who suffer from the debilitating condition.
The last meeting of the group saw 50 people show up looking for mutual support, information and peace of mind. Needless to say, Jimmy Gossett, one of the founding members of the group, was both astonished and pleased at the response.
"It is so nice to meet so many people who have the same condition as you," said Gossett, explaining he doesn't wish the disease on anyone. "But when you have this kind of problem, having friends and meeting new ones who through sheer numbers can build you back up, that is a nice thing."
With each new group meeting, Gossett said more and more health professionals work to assist in any way they can. Gossett said in the upcoming meeting, set forTuesday, June 12 at 10 a.m.at the Fifteenth Avenue Baptist Church in Meridian, three health professionals will be on hand to lend their expertise in the realm of Parkinson's Disease (PD).
"We will have physical therapists and speech pathologists on hand to help with information on what we face as PD sufferers," Gossett said. "But we will have fun, laugh, and fellowship. That is the best therapy we can have."
Gossett said the therapists will bring with them years of experience in dealing with PD sufferers. He said the health professionals will address such issues as speech deficits including reduced volume in their voices, decreased intelligibility, poor breath support and swallowing. Speech pathologists Angela Ramsey and Lesley Smith will be speaking to the group about oral motor exercises, respiratory exercises, and patterning techniques. The subject of neuromuscular e-stim to improve speech and swallowing will be covered.
Also, Amanda Sayers, a physical therapist, will be on hand to discuss some exercise techniques and different treatment approaches for the group as related to gait patterns, how to deal with "freezing" and tremors, and safety precautions.
"Each of these presentations will be followed by question and answer sessions so each person there can get the answers unique to their conditions," said Gossett.
Gossett said everyone is invited. He said he hopes that all PD suffers, not only in Meridian and Lauderdale County, but also throughout the East Mississippi area, will come and discover this group so they can seek the help and support so many sufferers need.
"It is all up to us, the PD sufferer, to increase our knowledge and understanding of this condition so that we can better cope with it," Gossett said. "We encourage those family members who have a person suffering from PD to come as well so they can get a firm grip on what their loved one is going through."
Here is the original post:
Parkinson's group to meet
Parkinson's Disease – Smelling Test For Early Detection
Editor's Choice Main Category: Parkinson's Disease Article Date: 16 Jun 2012 - 0:00 PDT
Current ratings for: 'Parkinson's Disease - Smelling Test For Early Detection'
5 (1 votes)
Researchers have now discovered that the sense of smell provides valuable indications. Hyposmia, i.e. losing the ability to smell for no known cause could be a markers for the non-motor signs of Parkinson's disease. Dr Ulrich Liebetrau, chief physician for Parkinson's consultations at the Neurological Department of Kliniken der Stadt Kln, declared at the 22nd Meeting of the European Neurological Society (ENS) in Prague: "Smelling tests in doctors' offices are suitable for detecting hyposmia but so too are tests conducted in public places such as pedestrian zones."
Parkinson's is a very common neurological slowly progressive disease that usually affects individuals aged between 50 and 60 years. In Germany alone there are about 300,000 people diagnosed with Parkinson's. Scientists still remain uncertain for the reasons of cell death occurring in the substantia nigra in the basal ganglia of the brain of Parkinson's patients, but suspect that genetic factors may be involved. The cell death causes a shortage of dopamine, a neurotransmitter, which leads to loss of control over voluntary and involuntary movements. German neurologists from Cologne have now tested a new early detection method for subtle signs of Parkinson's which focuses on the partial loss of the sense of smell, which they based on previous studies that demonstrated that one in ten people with hyposmia develop Parkinson's in later years.
Dr Liebetrau explained: "Our objective was to reach as many people with hyposmia as we possibly could."
The team used an unusual method for their trial. They performed a public smelling test on a Saturday in a banqueting hall in Cologne's pedestrian district that is well known. Liebetrau described the requirements the venue needed to fulfill, saying:
They asked 187 participants to smell vanilla, lemon, cloves and lavender to smell. Overall, 46 participants were identified as having hyposmia, who were all offered a follow-up at the City of Cologne Clinics (Kliniken der Stadt Kln). Dr Liebetrau explained: "The test was to be followed up by a professional examination done by neurologists and ENT specialists at a separate time and place. After all, hyposmia can be a sign of any number of diseases."
The result revealed that three of the 46 individuals with hyposmia were diagnosed with Parkinson's, even though they had no former knowledge prior to the test that they were affected by the disease.
One of the key advantages of low-threshold tests is that diseases that would otherwise go undetected are identified early, which also prevents these diseases from becoming chronic. Early diagnosis is advantageous, even if they involve severe neurological disorders like Parkinson's.
Read the original here:
Parkinson's Disease - Smelling Test For Early Detection
Vitamin K2: New hope for Parkinson's patients?
Public release date: 11-May-2012 [ | E-mail | Share ]
Contact: Patrik Verstreken 32-497-422-165 VIB (the Flanders Institute for Biotechnology)
Neuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson's using vitamin K2. His discovery gives hope to Parkinson's patients. This research was done in collaboration with colleagues from Northern Illinois University (US) and will be published this evening on the website of the authorative journal Science.
"It appears from our research that administering vitamin K2 could possibly help patients with Parkinson's. However, more work needs to be done to understand this better," says Patrik Verstreken.
Malfunctioning power plants are at the basis of Parkinson's.
If we looked at cells as small factories, then mitochondria would be the power plants responsible for supplying the energy for their operation. They generate this energy by transporting electrons. In Parkinson's patients, the activity of mitochondria and the transport of electrons have been disrupted, resulting in the mitochondria no longer producing sufficient energy for the cell. This has major consequences as the cells in certain parts of the brain will start dying off, disrupting communication between neurons. The results are the typical symptoms of Parkinson's: lack of movement (akinesia), tremors and muscle stiffness.
The exact cause of this neurodegenerative disease is not known. In recent years, however, scientists have been able to describe several genetic defects (mutations) found in Parkinson's patients, including the so-called PINK1 and Parkin mutations, which both lead to reduced mitochondrial activity. By studying these mutations, scientists hope to unravel the mechanisms underlying the disease process.
Paralyzed fruit flies
Fruit flies (Drosophila) are frequently used in lab experiments because of their short life spans and breeding cycles, among other things. Within two weeks of her emergence, every female is able to produce hundreds of offspring. By genetically modifying fruitflies, scientists can study the function of certain genes and proteins. Patrik Verstreken and his team used fruitflies with a genetic defect in PINK1 or Parkin that is similar to the one associated with Parkinson's. They found that the flies with a PINK1 or Parkin mutation lost their ability to fly.
Upon closer examination, they discovered that the mitochondria in these flies were defective, just as in Parkinson's patients. Because of this they generated less intracellular energy energy the insects needed to fly. When the flies were given vitamin K2, the energy production in their mitochondria was restored and the insects' ability to fly improved. The researchers were also able to determine that the energy production was restored because the vitamin K2 had improved electron transport in the mitochondria. This in turn led to improved energy production.
Healthbeat Report: Predicting Parkinson's
by Sylvia Perez and Christine Tressel
May 24, 2012 (CHICAGO) -- Colonoscopies are known for detecting early signs of cancer in the colon. Now Chicago researchers say this common test may help reveal who might be at risk of developing Parkinson's disease. They have discovered a clue in the gut that could be a game changer for early diagnosis and even treating the disease.
Richard Fiske Bailey says even he had a hard time realizing something was happening with his body. It was the way he was driving his sports car that caught the attention of friends.
"When I went to shift gears I would reach down with my left hand and shift I would shift with my left hand instead of my right hand, I never noticed it. And people would start to say, what is wrong," Fiske said.
It took a long time but eventually he had a diagnosis: Parkinson's disease.
"I was formally diagnosed in 2003 by my fifth neurologist," Fiske said.
A slight tremor in a hand, tense muscles and slow movements are some of the more distinctive signs suggesting Parkinson's disease. But even these can be confused with other conditions. That means thousands of cases are not diagnosed until a lot of brain cells are gone.
Parkinson's disease occurs when the nerve cells in the brain that make a chemical called dopamine are slowly destroyed. No one is sure why that happens.
Now researchers are turning to what would seem an unlikely source of a brain disorder: the gut.
"This area of research is really hot right now, and we think it's really important," said Dr. Kathleen Shannon, neurologist, Rush University Medical Center
Parkinson's patients to swamp homes
Australia's nursing homes will be swamped by a tidal wave of Parkinson's sufferers unless governments act now, an expert warns.
A Sydney-based Parkinson's disease expert says rates are expected to jump 80 per cent over the next 20 years because of Australia's aging population.
Currently 64,000 people have the progressive brain disease that causes uncontrollable tremors, loss of movement and bowel and bladder problems.
Associate Professor Simon Lewis from the University of Sydney is expected to present new research on the benefits of community-based Parkinson's nurses at a nursing conference on the Gold Coast on Friday.
Professor Lewis says Australia must adopt the UK approach of employing the specialist nurses or pay the price in nursing home care costs.
'You have to have a way of addressing this tidal wave of patients who are coming over the next 20 years,' he told AAP.
His research indicates that access to specialist nurses in the community can stave off the need for nursing home accommodation.
He compared the health of Parkinson's sufferers and their carers in Shoalhaven, NSW, before and six months after they were placed in the care of a specialist nurse.
'Very clearly what we saw is that during the time they had been seeing the nurse the patient's health had improved,' he said.
'More importantly, the carers themselves reported that their own health had improved.'
Here is the original post:
Parkinson's patients to swamp homes
OPKO Health and The Scripps Research Institute Announce Global License Agreement for a Novel Compound That Blocks …
MIAMI & JUPITER, Fla.--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK - News) and The Scripps Research Institute today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinsons disease. Under the terms of the agreement, The Scripps Research Institute has granted to OPKO Health exclusive worldwide rights to develop, manufacture and commercialize SR 3306 and related compounds that inhibit a class of enzymes called jun-N-terminal kinsases (JNK) that play an important role in neuron survival. The new compound, a small molecule known as SR-3306, would potentially be the first to protect the brain from the ravages of Parkinson's disease.
This licensing agreement will help insure that the development of this promising compound keeps moving forward, said Scripps Research Professor Philip LoGrasso, whose laboratory has led the research on the compound to date. This is one of the best opportunities we have for the development of an effective neuroprotective treatment for Parkinsons patients.
We are excited to be working with Dr. LoGrasso and The Scripps Research Institute to develop this important compound which could prevent the progression of Parkinsons disease and not just treat the symptoms of the disease, said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. Parkinson's disease, a degenerative neurological disorder that reduces the brain's ability to produce dopamine, affects about one million Americans. Currently prescribed drugs for Parkinsons disease including levodopa and so-called MAO-B inhibitors can counteract symptoms of the disease but not stop its progression.
SR-3306 was described in a pair of studies led by Dr. LoGrasso and published in February 2011 in the journal ACS Chemical Neuroscience.
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, Scripps Research has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including three Nobel laureates work toward their next discoveries. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see http://www.scripps.edu.
About OPKO Health, Inc.
OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
Forward Looking Statements:
Read the original:
OPKO Health and The Scripps Research Institute Announce Global License Agreement for a Novel Compound That Blocks ...
Discover New Treatments For Parkinson's Disease
Nearly one million people in the United States are living with Parkinson's Disease. Although there is no cure, there are medications and surgical options that can help manage symptoms optimally.
Winthrop-University Hospital's Perspectives in Health series will offer a free seminar for the public, "Discover New Treatments for Parkinson's Disease," on Tuesday,
March 20, at 7:00 PM. The program will be held at Winthrop's Community Outreach Center, located at 101 Mineola Boulevard at the corner of Second Street in Mineola. The speakers, who are two leading experts in the field of Parkinson's, will provide information about the most advanced treatment options and will explain the evaluation process for treating the disease.
Nora L. Chan, MD, Director of the Movement Disorders Program at Winthrop, will discuss how to optimize the medical management of the disease, and address the nonmovement related issues of Parkinson's, such as problems with cognition, depression, fatigue, and sleep.
Brian Synder, MD, will explain surgical techniques, including deep brain stimulation (DBS), an innovative, sophisticated technology that targets regions deep within the brain to control motor symptoms. A question and answer period will be included in the program.
Attendees are asked to arrive at 6:45 PM for registration. Parking and the entrance are available in the rear of the building. Seating is limited and pre-registration is required. To reserve a space, please call (516) 663-8300.
For information on other programs at the Hospital, please call 1-866-WINTHROP, or visit http://www.winthrop.org/communityprograms.
Original post:
Discover New Treatments For Parkinson's Disease
Parkinson's disease stopped in animal model: Molecular 'tweezers' break up toxic aggregations of proteins
ScienceDaily (Mar. 2, 2012) Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.
While it's not known what exactly causes the disease, evidence points to one particular culprit: a protein called -synuclein. The protein, which has been found to be common to all patients with Parkinson's, is thought to be a pathway to the disease when it binds together in "clumps," or aggregates, and becomes toxic, killing the brain's neurons.
Now, scientists at UCLA have found a way to prevent these clumps from forming, prevent their toxicity and even break up existing aggregates.
UCLA professor of neurology Jeff Bronstein and UCLA associate professor of neurology Gal Bitan, along with their colleagues, report the development of a novel compound known as a "molecular tweezer," which in a living animal model blocked -synuclein aggregates from forming, stopped the aggregates' toxicity and, further, reversed aggregates in the brain that had already formed. And the tweezers accomplished this without interfering with normal brain function.
The research appears in the current online edition of the journal Neurotherapeutics.
There are currently more than 30 diseases with no cure that are caused by protein aggregation and the resulting toxicity to the brain or other organs, including Parkinson's, Alzheimer's and Type 2 diabetes. It is therefore critical, Bronstein said, to find a way to stop this aggregation process. Over the last two decades, researchers and pharmaceutical companies have attempted to develop drugs that would prevent abnormal protein aggregation, but so far, they have had little or no success.
While these aggregates are a natural target for a drug, finding a therapy that targets only the aggregates is a complicated process, Bronstein said. In Parkinson's, for example, the protein implicated in the disorder, -synuclein, is naturally ubiquitous throughout the brain.
"Its normal function is not well understood, but it may play a role in aiding communication between neurons," Bronstein said. "The trick, then, is to prevent the -synuclein protein aggregates and their toxicity without destroying -synuclein's normal function, along with, of course, other healthy areas of the brain.
Molecular tweezer
Bronstein collaborated with Bitan, who had been working with a particular molecular tweezer he had developed called CLR01. Molecular tweezers are complex molecular compounds that are capable of binding to other proteins. Shaped like the letter "C," these compounds wrap around chains of lysine, a basic amino acid that is a constituent of most proteins.
Lawrence dives in for Parkinson's
Swim coach Laurie Lawrence.
APN
OLYMPIC and world champion swim coach Laurie Lawrence will add his support to a call for the establishment of a national network of community-based nurses following the publishing of new research into Parkinson's disease.
The findings of the Australian-first Shoalhaven Project reveal the valuable role played by community-based nurses in supporting people living with this devastating, neurodegenerative disease.
This study reveals the crucial role nurses play in significantly improving the quality of life of more than 1-in-350 (64,000) Australians affected by this disease.
One of those 64,000 is Ian Findlay, the former Australian butterfly champion and life-long friend of Lawrence. Findlay was diagnosed with young onset Parkinson's at 40 years of age in 2004.
Lawrence is now urging the Government to fund more community-based Parkinson's nurses in support of Findlay and other sufferers.
"I coached Ian as a young athlete and I know of no one who trained harder than he did. Once he finished his competitive career, I asked Ian to become my assistant coach. We've been friends for 28 years.
"He is a true champion. Ian has tremendous courage and has overcome many obstacles - physical and mental - throughout his distinguished career. Since his diagnosis, he has changed from being an outgoing, bouncy fella to someone who is more introspective and cautious.
"He works incredibly hard to fight the symptoms of Parkinson's with assistance from his hospital-based nurse and his wife, Nicole, who has given up her career as a school teacher to care for him. Both are integral to his physical and mental wellbeing. Having access to a local, community-based nurse would further complement his support network," said Mr Lawrence.
Original post:
Lawrence dives in for Parkinson's